HC Wainwright Comments on Immunocore FY2029 Earnings

Immunocore Holdings plc (NASDAQ:IMCR) – Investment analysts at HC Wainwright issued their FY2029 earnings estimates for shares of Immunocore in a note issued to investors on Monday, January 27th. HC Wainwright analyst P. Trucchio expects that the company will post earnings per share of $7.53 for the year. HC Wainwright currently has a “Buy” rating and a $100.00 target price on the stock. The consensus estimate for Immunocore’s current full-year earnings is ($0.94) per share.

Immunocore (NASDAQ:IMCR) last announced its quarterly earnings data on Wednesday, November 6th. The company reported $0.17 EPS for the quarter, beating the consensus estimate of ($0.33) by $0.50. The firm had revenue of $80.25 million for the quarter, compared to the consensus estimate of $78.94 million. Immunocore had a negative net margin of 15.87% and a negative return on equity of 12.84%. The company’s revenue was up 23.7% on a year-over-year basis. During the same period last year, the firm earned ($0.59) EPS.

IMCR has been the topic of several other reports. Guggenheim downgraded shares of Immunocore from a “buy” rating to a “neutral” rating in a research report on Monday, October 7th. Mizuho downgraded shares of Immunocore from an “outperform” rating to a “neutral” rating and reduced their price target for the company from $72.00 to $38.00 in a report on Monday, November 11th. Morgan Stanley reiterated an “equal weight” rating and issued a $35.00 price target (down from $74.00) on shares of Immunocore in a report on Friday, December 13th. Needham & Company LLC reiterated a “buy” rating and issued a $71.00 price target on shares of Immunocore in a report on Friday, January 10th. Finally, UBS Group began coverage on shares of Immunocore in a report on Thursday, October 24th. They issued a “sell” rating and a $24.00 price target on the stock. One investment analyst has rated the stock with a sell rating, four have given a hold rating and eight have given a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $65.64.

Immunocore Stock Down 1.4 %

Shares of IMCR stock opened at $31.64 on Tuesday. The company has a market capitalization of $1.58 billion, a price-to-earnings ratio of -33.30 and a beta of 0.76. Immunocore has a one year low of $27.69 and a one year high of $76.98. The company’s fifty day moving average price is $30.53 and its 200-day moving average price is $33.22. The company has a debt-to-equity ratio of 1.03, a current ratio of 3.78 and a quick ratio of 3.76.

Hedge Funds Weigh In On Immunocore

A number of institutional investors and hedge funds have recently made changes to their positions in IMCR. Wellington Management Group LLP grew its stake in shares of Immunocore by 10.5% in the 3rd quarter. Wellington Management Group LLP now owns 7,048,833 shares of the company’s stock worth $219,430,000 after buying an additional 668,382 shares in the last quarter. Primecap Management Co. CA grew its stake in shares of Immunocore by 26.7% in the 3rd quarter. Primecap Management Co. CA now owns 2,472,020 shares of the company’s stock worth $76,954,000 after buying an additional 520,950 shares in the last quarter. Millennium Management LLC grew its stake in shares of Immunocore by 124.4% in the 2nd quarter. Millennium Management LLC now owns 600,954 shares of the company’s stock worth $20,366,000 after buying an additional 333,167 shares in the last quarter. Two Sigma Advisers LP boosted its stake in shares of Immunocore by 65.6% during the 3rd quarter. Two Sigma Advisers LP now owns 757,700 shares of the company’s stock worth $23,587,000 after purchasing an additional 300,200 shares during the period. Finally, Principal Financial Group Inc. boosted its stake in shares of Immunocore by 25.0% during the 3rd quarter. Principal Financial Group Inc. now owns 546,318 shares of the company’s stock worth $17,007,000 after purchasing an additional 109,206 shares during the period. 84.50% of the stock is owned by hedge funds and other institutional investors.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.